Francesca Carlomagno

7.9k total citations · 1 hit paper
92 papers, 6.2k citations indexed

About

Francesca Carlomagno is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Francesca Carlomagno has authored 92 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 39 papers in Oncology and 28 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Francesca Carlomagno's work include Cancer-related Molecular Pathways (28 papers), Thyroid Cancer Diagnosis and Treatment (28 papers) and HER2/EGFR in Cancer Research (13 papers). Francesca Carlomagno is often cited by papers focused on Cancer-related Molecular Pathways (28 papers), Thyroid Cancer Diagnosis and Treatment (28 papers) and HER2/EGFR in Cancer Research (13 papers). Francesca Carlomagno collaborates with scholars based in Italy, United States and France. Francesca Carlomagno's co-authors include Massimo Santoro, Alfredo Fusco, Massimo Santoro, Rosa Marina Melillo, Giancarlo Vecchio, Teresa Guida, Giuliana Salvatore, Suresh Anaganti, Michèle Grieco and Anderson J. Ryan and has published in prestigious journals such as Science, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Francesca Carlomagno

88 papers receiving 6.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B

1995 629 citations Massimo Santoro, Francesca Carlomagno et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francesca Carlomagno Italy	42	2.9k	2.5k	2.4k	880	823	92	6.2k
Rosa Marina Melillo Italy	47	3.6k 1.2×	2.7k 1.1×	2.6k 1.1×	501 0.6×	762 0.9×	100	6.8k
Italia Bongarzone Italy	45	3.8k 1.3×	3.3k 1.3×	2.9k 1.2×	500 0.6×	1.2k 1.5×	113	7.4k
Maria Grazia Borrello Italy	41	2.6k 0.9×	1.6k 0.7×	1.6k 0.7×	420 0.5×	697 0.8×	86	4.9k
Gennaro Chiappetta Italy	50	4.3k 1.5×	2.5k 1.0×	2.1k 0.9×	634 0.7×	834 1.0×	110	7.4k
Jeffrey A. Knauf United States	47	4.2k 1.4×	6.4k 2.6×	3.7k 1.6×	835 0.9×	1.5k 1.8×	85	9.6k
Mercedes Robledo Spain	44	2.2k 0.8×	2.2k 0.9×	1.2k 0.5×	575 0.7×	658 0.8×	195	6.0k
Valentine M. Macaulay United Kingdom	35	2.9k 1.0×	1.7k 0.7×	1.3k 0.5×	626 0.7×	436 0.5×	73	4.5k
Natalia S. Pellegata Germany	33	1.5k 0.5×	1.3k 0.5×	1.8k 0.7×	290 0.3×	341 0.4×	94	4.3k
Massimo Santoro Italy	54	4.4k 1.5×	7.6k 3.1×	4.2k 1.8×	1.0k 1.2×	1.8k 2.2×	114	11.6k
Maria Teresa Berlingieri Italy	32	2.8k 1.0×	1.6k 0.6×	1.3k 0.5×	296 0.3×	651 0.8×	51	4.4k

Countries citing papers authored by Francesca Carlomagno

Since Specialization

Citations

This map shows the geographic impact of Francesca Carlomagno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesca Carlomagno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesca Carlomagno more than expected).

Fields of papers citing papers by Francesca Carlomagno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesca Carlomagno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesca Carlomagno. The network helps show where Francesca Carlomagno may publish in the future.

Co-authorship network of co-authors of Francesca Carlomagno

This figure shows the co-authorship network connecting the top 25 collaborators of Francesca Carlomagno. A scholar is included among the top collaborators of Francesca Carlomagno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesca Carlomagno. Francesca Carlomagno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Federico, Giorgia, et al.. (2022). NCOA4 links iron bioavailability to DNA metabolism. Cell Reports. 40(7). 111207–111207. 22 indexed citations

Yan, Wei, Fengping Lv, Francesca Carlomagno, et al.. (2021). Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry. 216. 113265–113265. 20 indexed citations

Nai, Antonella, Maria Rosa Lidonnici, Giorgia Federico, et al.. (2017). The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia. Blood. 130. 224–224. 1 indexed citations

Falco, Valentina De, Francesca Carlomagno, Hongyu Li, & Massimo Santoro. (2017). The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism. 31(3). 307–318. 33 indexed citations

Frett, Brendan, et al.. (2014). Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation. European Journal of Medicinal Chemistry. 86. 714–723. 19 indexed citations

Falco, Valentina De, Magesh Muthu, Liborio Torregrossa, et al.. (2013). Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 98(5). E811–E819. 74 indexed citations

Carlomagno, Francesca & Massimo Santoro. (2011). A roadmap for targeted therapies. Nature Reviews Endocrinology. 7(2). 65–67. 12 indexed citations

Nappi, Tito Claudio, Paolo Salerno, Horst Zitzelsberger, et al.. (2009). Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma. Cancer Research. 69(5). 1916–1923. 53 indexed citations

Castellone, Maria Domenica, Francesca Carlomagno, Giuliana Salvatore, & Massimo Santoro. (2008). Receptor tyrosine kinase inhibitors in thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism. 22(6). 1023–1038. 27 indexed citations

10.

Minopoli, Giuseppina, Fabiana Passaro, Luigi Aloia, et al.. (2007). Receptor- and Non-Receptor Tyrosine Kinases Induce Processing of the Amyloid Precursor Protein: Role of the Low-Density Lipoprotein Receptor-Related Protein. Neurodegenerative Diseases. 4(2-3). 94–100. 7 indexed citations

11.

Guida, Teresa, Suresh Anaganti, Richard Gedrich, et al.. (2007). Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants. Clinical Cancer Research. 13(11). 3363–3369. 61 indexed citations

12.

Iavarone, Carlo, Mario Acunzo, Francesca Carlomagno, et al.. (2006). Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene. Journal of Biological Chemistry. 281(15). 10567–10576. 42 indexed citations

13.

Carlomagno, Francesca & Massimo Santoro. (2004). Identification of RET Kinase Inhibitors as Potential New Treatment for Sporadic and Inherited Thyroid Cancer. Journal of Chemotherapy. 16(sup4). 49–51. 25 indexed citations

14.

Carlomagno, Francesca, Donata Vitagliano, Teresa Guida, et al.. (2002). ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.. PubMed. 62(24). 7284–90. 481 indexed citations

15.

Dunning, Alison M., Francine Durocher, Catherine S. Healey, et al.. (2000). The Extent of Linkage Disequilibrium in Four Populations with Distinct Demographic Histories. The American Journal of Human Genetics. 67(6). 1544–1554. 143 indexed citations

16.

Santoro, Massimo, Francesca Carlomagno, Rosa Marina Melillo, et al.. (1999). Molecular mechanisms of RET activation in human neoplasia. Journal of Endocrinological Investigation. 22(10). 811–819. 33 indexed citations

17.

Cosma, Maria Pia, Monica Cardone, Francesca Carlomagno, & Vittorio Colantuoni. (1998). Mutations in the Extracellular Domain Cause RET Loss of Function by a Dominant Negative Mechanism. Molecular and Cellular Biology. 18(6). 3321–3329. 51 indexed citations

18.

Carlomagno, Francesca, Gabriella De Vita, Maria Teresa Berlingieri, et al.. (1996). Molecular heterogeneity of RET loss of function in Hirschsprung's disease.. The EMBO Journal. 15(11). 2717–2725. 107 indexed citations

19.

Santoro, Massimo, Yukihito Ishizaka, Toshikazu Ushijima, et al.. (1993). Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. British Journal of Cancer. 68(3). 460–464. 60 indexed citations

20.

Santoro, Massimo, Francesca Carlomagno, Ian Hay, et al.. (1992). Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.. Journal of Clinical Investigation. 89(5). 1517–1522. 307 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact